Profile data is unavailable for this security.
About the company
Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation, and immunology (NI&I) indications with high unmet need. Its pipeline includes PIPE-791, CTX-343, and PIPE-307. Its lead asset, PIPE-791, is novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) in development for idiopathic pulmonary fibrosis (IPF) and progressive multiple sclerosis (Progressive MS). The Company is developing CTX-343, a peripherally restricted LPA1R antagonist to further expand clinical indications involving LPA1R antagonism. Its second drug candidate, PIPE-307, is a novel, small molecule, selective inhibitor of M1R, which is in clinical development for the potential treatment of depression and relapse remitting MS (RRMS).
- Revenue in USD (TTM)--
- Net income in USD--
- Incorporated2009
- Employees31.00
- LocationContineum Therapeutics Inc10578 Science Center Drive, Suite 200SAN DIEGO 92121United StatesUSA
- Phone+1 (858) 333-5280
- Fax+1 (302) 655-5049
- Websitehttps://www.contineum-tx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Taysha Gene Therapies Inc | 12.87m | -114.34m | 440.63m | 52.00 | -- | 3.98 | -- | 34.23 | -0.8987 | -0.8987 | 0.0643 | 0.5406 | 0.0913 | -- | -- | 247,557.70 | -81.11 | -- | -116.01 | -- | -- | -- | -888.18 | -- | -- | -- | 0.2598 | -- | 517.55 | -- | 32.80 | -- | -- | -- |
Fate Therapeutics Inc | 12.32m | -175.72m | 441.85m | 181.00 | -- | 1.11 | -- | 35.87 | -1.71 | -1.71 | 0.1185 | 3.49 | 0.0221 | -- | 6.35 | 68,049.73 | -31.56 | -31.82 | -33.99 | -36.05 | -- | -- | -1,426.67 | -359.33 | -- | -- | 0.00 | -- | -34.03 | 68.05 | 42.88 | -- | 21.72 | -- |
C4 Therapeutics Inc | 29.38m | -107.87m | 442.37m | 145.00 | -- | 1.78 | -- | 15.06 | -1.90 | -1.90 | 0.4944 | 3.59 | 0.0777 | -- | 26.77 | 202,606.90 | -28.53 | -25.91 | -33.00 | -29.45 | -- | -- | -367.17 | -292.35 | -- | -- | 0.00 | -- | -33.25 | 1.40 | -3.37 | -- | -8.68 | -- |
Absci Corp | 3.25m | -92.26m | 451.95m | 155.00 | -- | 2.04 | -- | 139.06 | -0.9331 | -0.9331 | 0.0327 | 1.95 | 0.0128 | -- | 2.03 | 20,967.74 | -36.20 | -- | -40.23 | -- | -- | -- | -2,838.89 | -- | -- | -129.46 | 0.0284 | -- | -0.5046 | -- | -5.40 | -- | -- | -- |
ACELYRIN Inc | 0.00 | -299.80m | 459.12m | 130.00 | -- | 0.8061 | -- | -- | -3.06 | -3.06 | 0.00 | 5.71 | 0.00 | -- | -- | 0.00 | -40.33 | -- | -43.71 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -489.21 | -- | -- | -- |
SAGE Therapeutics Inc | 97.24m | -445.67m | 463.37m | 487.00 | -- | 0.7359 | -- | 4.77 | -7.41 | -7.41 | 1.62 | 10.31 | 0.1093 | -- | 6.75 | 199,679.70 | -50.09 | -21.88 | -55.24 | -23.30 | 95.47 | 99.63 | -458.30 | -131.50 | -- | -- | 0.00 | -- | 1,024.84 | -0.8606 | -1.63 | -- | -28.01 | -- |
Verve Therapeutics Inc | 20.65m | -192.65m | 466.28m | 255.00 | -- | 0.8531 | -- | 22.58 | -2.59 | -2.59 | 0.275 | 6.46 | 0.032 | -- | 8.05 | 80,972.55 | -29.87 | -- | -31.67 | -- | -- | -- | -933.03 | -- | -- | -- | 0.00 | -- | 505.77 | -- | -27.12 | -- | -- | -- |
Anavex Life Sciences Corp | 0.00 | -41.53m | 466.38m | 40.00 | -- | 3.59 | -- | -- | -0.5012 | -0.5012 | 0.00 | 1.53 | 0.00 | -- | -- | 0.00 | -27.75 | -40.04 | -30.03 | -43.97 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 0.9857 | -- | -- | -- |
Aura Biosciences Inc | 0.00 | -80.69m | 473.74m | 88.00 | -- | 2.47 | -- | -- | -1.79 | -1.79 | 0.00 | 3.86 | 0.00 | -- | -- | 0.00 | -39.26 | -- | -41.21 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -30.03 | -- | -- | -- |
Contineum Therapeutics Inc | -100.00bn | -100.00bn | 475.62m | 31.00 | -- | 2.19 | -- | -- | -- | -- | -- | 8.46 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 193.68 | -- | -- | -- |
Prime Medicine Inc | 591.00k | -217.44m | 477.72m | 234.00 | -- | 2.43 | -- | 808.33 | -2.16 | -2.16 | 0.0058 | 1.64 | 0.0022 | -- | -- | 2,525.64 | -80.45 | -- | -88.55 | -- | -- | -- | -36,791.71 | -- | -- | -- | 0.00 | -- | -- | -- | -39.52 | -- | -- | -- |
Mind Medicine (MindMed) Inc | 0.00 | -102.04m | 489.13m | 57.00 | -- | 2.17 | -- | -- | -2.26 | -2.26 | 0.00 | 2.80 | 0.00 | -- | -- | 0.00 | -49.75 | -- | -61.24 | -- | -- | -- | -- | -- | -- | -- | 0.1072 | -- | -- | -- | -68.55 | -- | -- | -- |
Compass Pathways PLC (ADR) | 0.00 | -139.21m | 499.23m | 186.00 | -- | 2.21 | -- | -- | -2.30 | -2.30 | 0.00 | 3.31 | 0.00 | -- | -- | 0.00 | -57.01 | -40.85 | -61.38 | -44.48 | -- | -- | -- | -- | -- | -52.52 | 0.1151 | -- | -- | -- | -29.46 | -- | -12.68 | -- |
Entrada Therapeutics Inc | 239.40m | 104.44m | 507.77m | 168.00 | 4.61 | 1.18 | 4.71 | 2.12 | 2.96 | 2.96 | 6.92 | 11.57 | 0.445 | -- | 41.93 | 1,505,642.00 | 19.41 | -- | 24.17 | -- | -- | -- | 43.63 | -- | -- | -- | 0.00 | -- | -- | -- | 92.93 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Suvretta Capital Management LLCas of 30 Jun 2024 | 2.05m | 10.81% |
Perceptive Advisors LLCas of 30 Jun 2024 | 1.57m | 8.25% |
Sectoral Asset Management, Inc.as of 30 Jun 2024 | 800.89k | 4.22% |
HHLR Advisors Ltd.as of 30 Jun 2024 | 669.34k | 3.52% |
Franklin Advisers, Inc.as of 30 Jun 2024 | 625.02k | 3.29% |
The Vanguard Group, Inc.as of 30 Jun 2024 | 463.40k | 2.44% |
Altium Capital Management LPas of 30 Jun 2024 | 429.34k | 2.26% |
BlackRock Fund Advisorsas of 30 Jun 2024 | 364.84k | 1.92% |
Fidelity Management & Research Co. LLCas of 30 Jun 2024 | 323.60k | 1.70% |
Baker Bros. Advisors LPas of 30 Jun 2024 | 312.50k | 1.65% |